Gilead Sciences (GILD) News
NASDAQ: GILDHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
151.17+4.07 (+2.77%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
GILD news summary
We found 29 recent headlines mentioning Gilead Sciences (GILD): 6 in the past week and 23 in the past 30 days, most often from Nasdaq, Seeking Alpha. For price context, GILD is up 2.77% at $151.17. The most recent story, "Gilead Sciences (GILD) Laps the Stock Market: Here's Why", was published by Nasdaq on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Gilead Sciences headlines
- Gilead Sciences (GILD) Laps the Stock Market: Here's WhyGilead Sciences (GILD) closed the most recent trading day at $151.17, moving +2.77% from the previous trading session.Nasdaq
- Weekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data(RTTNews) - This week, biopharmaceutical companies saw a busy week of regulatory decisions, strategic partnerships and clinical developments, alongside pipeline setbacks and workforce reductions.NasdaqABBV, ALVO, ARGX, BBIO
- Noteworthy ETF Outflows: TQQQ, NFLX, STX, GILDLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro QQQ (Symbol: TQQQ) where we have detected an…NasdaqTQQQ, NFLX, STX, GILD
- How to Boost Your Portfolio with Top Medical Stocks Set to Beat EarningsFinding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.NasdaqIOVA, GILD
- Nasdaq 100 Movers: ALAB, HONIVIn early trading on Wednesday, shares of Honeywell International topped the list of the day's best performing components of the Nasdaq 100 index, trading up 7.5%. Year to date, Honeywell…NasdaqALAB, NBIS, GILD
- Gilead: Buying Growth Isn't Free, And The Discounted Cash Flow Model Knows ItSeeking Alpha
- Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should KnowGilead Sciences (GILD) closed the most recent trading day at $144.74, moving 1.87% from the previous trading session.Nasdaq
- Notable ETF Inflow Detected - XLV, ABBV, TMO, GILDLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street Health Care Select Sector SPDR ETF (Symbol: XLV) where…NasdaqXLV, ABBV, TMO, GILD
- Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on ItGilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.Nasdaq
- Gilead Sciences (GILD) Declines More Than Market: Some Information for InvestorsIn the latest trading session, Gilead Sciences (GILD) closed at $149.45, marking a -1.21% move from the previous day.Nasdaq
- Pharmaceutical industry lobbying group names new CEO, Eric CantorSeeking Alpha
- Gilead: HIV Growth Is Not Enough At The Current PriceSeeking Alpha
- Gilead Sciences (GILD) Stock Moves 1.40%: What You Should KnowGilead Sciences (GILD) closed the most recent trading day at $152.67, moving +1.4% from the previous trading session.Nasdaq
- Notable ETF Inflow Detected - DGRO, PEP, GILD, RTXLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core Dividend Growth ETF (Symbol: DGRO) where we have…NasdaqDGRO, PEP, GILD, RTX
- BMY vs GILD: Which Biotech Stock Looks More Attractive Now?Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.NasdaqBMY, GILD
- J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?JNJ's growth gets a boost from new drug launches and pipeline wins, but Stelara's patent loss and MedTech headwinds remain key risks.NasdaqJNJ, LLY, GILD, PTGX
- Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to KnowRecently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.Nasdaq
- Gilead Expands Lenacapavir Access With New PAHO Deal in Latin AmericaGILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.NasdaqGILD, ALDX, ACIU, PGEN
- Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances3 Blue-Chip Stocks Built for a Rotating MarketGilead Sciences (NASDAQ:GILD) executives outlined plans to expand the company’s HIV prevention and treatment franchises while advancing oncology…Nasdaq
- Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking AlphaGILD, MS
- Gilead Sciences (GILD) Gains As Market Dips: What You Should KnowIn the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.42, denoting a +1.88% move from the preceding trading day.Nasdaq
- New FDA Drug Approvals - August 2026(RTTNews) - The U.S. Food and Drug Administration (FDA) granted approval to 13 drugs last month, comprising both new drug approvals and expanded indications for previously approved therapies.NasdaqBMY, BNTX, GILD, JAZZ
- Gilead Sciences, Inc. (GILD) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptSeeking Alpha
- Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeeking Alpha
- Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)Seeking Alpha
- Gilead Sciences: A Strong Quarter Hidden Behind A Bottom-Line LossSeeking Alpha
- Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call TranscriptSeeking Alpha
- Gilead Sciences, Inc. 2026 Q2 - Results - Earnings Call PresentationSeeking Alpha
- Gilead: Buy The Distortion Before Q2 Clears It UpSeeking Alpha